Stock Plotz n Ployz

[Stockz4O]

CHCG, CBPC, CPNE"
11/29/2006

Wall Street, NYC, Nov 29, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Today, wallstreetgrapevine.com, named; China 3C Group (OTC BB: CHCG), China BioPharma Inc. (OTC BB: CBPC), and CommercePlanet Inc. (OTC BB: CPNE); their "Stocks on the Rise."

China 3C Group (OTC BB: CHCG, http://www.marketwatch.com/tools/quotes/quotes.asp?symb=chcg&siteid=mktw )

China 3C Group Acquires Shanghai Joy & Harmony Electronics for $18.5M; Raises Full Year '06 Guidance

China 3C Group , a major retailer and distributor of consumer and business products, announced today that it has completed its acquisition of Shanghai Joy & Harmony Electronics Company Limited, a rapidly growing consumer electronics retail chain and web-based retailer in China.

In 2005, Shanghai Joy & Harmony recorded unaudited revenues of $12 million, compared to revenues of $5.5 million in 2004, a 118% growth rate. Net income for 2005 was $0.93 million, compared to a net income of $0.7 million for 2004. The projected revenues and net income for the full year 2006 are $38.75 million and $3.68 million.

Pursuant to the acquisition agreement, China 3C Group will acquire 100% of Shanghai Joy & Harmony in a cash and stock transaction valued at approximately $18.5 million. The company will issue to the shareholders an aggregate of 2,723,110 shares of restricted China 3C Group common stock, which is 5% of China 3C's outstanding shares, at $4.04 per share and pay cash of $7.5 million to the shareholders. The cash component is payable by China 3C as follows: $3 million within 10 business days after the closing and $4.5 million payable within six months after the closing.

China 3C Group is also increasing its guidance for the full year 2006 following its acquisition of Shanghai Joy & Harmony. The company raises its expected revenue guidance for 2006 to $181 million from $142 million, an increase of 27%, and is increasing its net income estimates by 35% to $14.4 million from $10.7 million. The company also projects earnings per share for 2006 will now be $0.27, an increase from its previous guidance of $0.22.

China 3C Group CEO Zhenggang Wang said, "With the acquisition of Shanghai Joy & Harmony, we have acquired two rapidly growing chains and more than 800 retail outlets. We have also increased our business line to include home electronics. We have successfully achieved our 2006 goal, and now we are ready to expand our business to Southern China and the entire China market."

About Shanghai Joy & Harmony

Shanghai Joy & Harmony Electronics Company Limited is a consumer electronics retail chain in Eastern China. It has 180 retail outlets in Shanghai City and Jiangsu Province. The company specializes in the sale of consumer electronics, including MP3 players, MP4 players, iPod, electronic dictionary, CD players, radios, Walkman, audio systems and speakers. The company is the authorized sales agent for well-known manufacturers in China like Tecsun Radio and Changhong ZARVA. For more information on the company, visit http://www.joyhe.cn.

About China 3C Group

China 3C Group is a leading retail chain operating over 800 retail outlets in Eastern China. The company specializes in selling 3C products (communication, information technology and digital) in China through its subsidiary Zhejiang Yong Xin Digital Technology Co., Ltd. Among China 3C's primary attributes is its efficient distribution network and rapid logistics system. The company's goal is to become the number one retailer of 3C products in China. For more information, visit http://www.china3cgroup.com.

A profile for investors can be accessed at http://www.hawkassociates.com/chcgprofile.aspx. For investor relations information regarding China 3C, contact Jason Yuan at [phone], e-mail: [e-mail], or Frank Hawkins or Ken AuYeung, Hawk Associates, at [phone], e-mail: [e-mail]. An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at http://www.hawkassociates.com and http://www.americanmicrocaps.com.

China BioPharma Inc. (OTC BB: CBPC, http://www.marketwatch.com/tools/quotes/quotes.asp?symb=cbpc&siteid=mktw )

China Biopharma and HYTE Research LLC Enter into Technology Partnership to Improve Safety and Efficacy of Human Vaccines

China Biopharma, Inc. , a biopharmaceutical company focused on developing and distributing human vaccine products in China, announced today that it has signed a letter of intent (LOI) with HYTE Research LLC, a New Jersey-based biotechnology research company. According to the agreement, the companies will jointly develop and commercialize Nano-Poly Enhancement technology for improving the effectiveness and reducing the side effects of human vaccines.

The resulting new technology will be used to combine with current human vaccines to achieve the immune-enhancing properties of surface antigen. Due to its superior field efficacy, this technology may be used to replace commonly used chemical adjuvants. An adjuvant is a substance that helps and enhances the pharmacological effect of a drug or increases the ability of an antigen to stimulate the immune system.

China Biopharma CEO Peter Wang stated, "Most of the vaccines produced in China do not use an adjuvant to improve the protective antibody responses after immunization. Our technology partnership with HYTE Research is very exciting as it would create a potentially 'disruptive technology' in the Chinese immunization market. We believe this technology could lead to wide commercial applications in the global human vaccine industry." China Biopharma will utilize its existing platforms to conduct the development and commercialization of the new technology. According to the LOI, China Biopharma will hold 55% of the intellectual property rights on the technology.

Chairman of HYTE Research LLC Dr. Yimin Yu commented, "China Biopharma's impressive portfolio of human vaccine products makes it an ideal partner. We share in their same goal, to develop and commercialize improving technologies that drive the industry's standard for best-in-practice human vaccines. We look forward to progressing with our development activities, and pursuing new marketing opportunities."

About China Biopharma Inc.

China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, Zhejiang Tianyuan Biotech Co., Ltd. and Hainan CITIC Biopharmaceutical Development Co., Ltd., the Company develops and distributes human vaccine products throughout the world's most populated country of China. Products include human vaccines against influenza, hemorrhagic fever and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international vaccine providers, China Biopharma is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.com.cn.